Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

• Published in: Cancers Vol. 12; no. 3; p. 657
• Main Authors: Chau, Ian, Fakih, Marwan, García-Alfonso, Pilar, Linke, Zdenĕk, Ruiz Casado, Ana, Marques, Eduardo Polo, Picard, Pascaline, Celanovic, Marina, Cartwright, Thomas
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.03.2020; MDPI
• Subjects: 5-Fluorouracil; Asthenia; Bevacizumab; Cancer therapies; Chemotherapy; Clinical medicine; Colorectal cancer; Colorectal carcinoma; Cytotoxicity; Diarrhea; Fistula; Irinotecan; Laboratories; Liver; Medical prognosis; Metastases; Metastasis; Monoclonal antibodies; Neutropenia; Oncology; Oxaliplatin; Ozone; Patients; Population; Safety; Survival; Targeted cancer therapy; Vascular endothelial growth factor; clinical practice; metastatic colorectal cancer; observational; aflibercept; antiangiogenic; FOLFIRI

For patients with metastatic colorectal cancer (mCRC) that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. This prospective, observational, noncomparative, post-authorization safety study (OZONE) evaluated the safety and effectivenes...